Kathrine RÃ¸e Redalen

List of Publications by Year
in descending order

Version: 2024-02-01

54 papers	914 citations	394421 19 h-index	526287 27 g-index
55 all docs	55 docs citations	55 times ranked	1661 citing authors

#	Article	IF	Citations
1	Five years, 20 volumes and 300 publications of Physics and Imaging in Radiation Oncology. Physics and Imaging in Radiation Oncology, 2022, 21, 123-125.	2.9	2
2	The 3rd ESTRO-EFOMP core curriculum for medical physics experts in radiotherapy. Radiotherapy and Oncology, 2022, 170, 89-94.	0.6	11
3	MRI-based automatic segmentation of rectal cancer using 2D U-Net on two independent cohorts. Acta OncolÃ³gica, 2022, 61, 255-263.	1.8	15
4	Development of an automated production process of [⁶⁴Cu][Cu (ATSM)] for positron emission tomography imaging and theranostic applications. Journal of Labelled Compounds and Radiopharmaceuticals, 2022, 65, 191-202.	1.0	6
5	Semi-automatic tumor segmentation of rectal cancer based on functional magnetic resonance imaging. Physics and Imaging in Radiation Oncology, 2022, 22, 77-84.	2.9	3
6	Strength training reduces radiation-induced bone deterioration and maintains lean mass in a rat model. Bone Reports, 2022, 16, 101369.	0.4	0
7	Uptake of circulating extracellular vesicles from rectal cancer patients and differential responses by human monocyte cultures. FEBS Open Bio, 2021, 11, 724-740.	2.3	2
8	The circulating soluble form of the CD40 costimulatory immune checkpoint receptor and liver metastasis risk in rectal cancer. British Journal of Cancer, 2021, 125, 240-246.	6.4	8
9	Alexithymia and professional quality of life in radiation oncology: The moderator effect of the professional profile. Radiotherapy and Oncology, 2021, 158, 48-54.	0.6	5
10	Sex disparities in vitamin D status and the impact on systemic inflammation and survival in rectal cancer. BMC Cancer, 2021, 21, 535.	2.6	0
11	Professional practice changes in radiotherapy physics during the COVID-19 pandemic. Physics and Imaging in Radiation Oncology, 2021, 19, 25-32.	2.9	5
12	Immunogenic cell death by neoadjuvant oxaliplatin and radiation protects against metastatic failure in high-risk rectal cancer. Cancer Immunology, Immunotherapy, 2020, 69, 355-364.	4.2	35
13	Sex-related differences in primary metastatic site in rectal cancer; associated with hemodynamic factors?. Clinical and Translational Radiation Oncology, 2020, 21, 5-10.	1.7	8
14	From multisource data to clinical decision aids in radiation oncology: The need for a clinical data science community. Radiotherapy and Oncology, 2020, 153, 43-54.	0.6	20
15	Future directions on the merge of quantitative imaging and artificial intelligence in radiation oncology. Physics and Imaging in Radiation Oncology, 2020, 15, 44-45.	2.9	3
16	Professional quality of life and burnout among medical physicists working in radiation oncology: The role of alexithymia and empathy. Physics and Imaging in Radiation Oncology, 2020, 15, 38-43.	2.9	22
17	Sex Differences and Tumor Blood Flow from Dynamic Susceptibility Contrast MRI Are Associated with Treatment Response after Chemoradiation and Long-term Survival in Rectal Cancer. Radiology, 2020, 297, 352-360.	7.3	14
18	The role of alexithymia and empathy on radiation therapistsâ€™ professional quality of life. Technical Innovations and Patient Support in Radiation Oncology, 2020, 15, 29-36.	1.9	11

#	Article	IF	Citations
19	Professional quality of life and burnout amongst radiation oncologists: The impact of alexithymia and empathy. Radiotherapy and Oncology, 2020, 147, 162-168.	0.6	22
20	Quantitative imaging for radiotherapy purposes. Radiotherapy and Oncology, 2020, 146, 66-75.	0.6	71
21	Hypoxia imaging and theranostic potential of [64Cu][Cu(ATSM)] and ionic Cu(II) salts: a review of current evidence and discussion of the retention mechanisms. EJNMMI Research, 2020, 10, 33.	2.5	34
22	High level of circulating vitamin D during neoadjuvant therapy may lower risk of metastatic progression in high-risk rectal cancer. BMC Cancer, 2019, 19, 488.	2.6	11
23	Circulating Exosomal miR-141-3p and miR-375 in Metastatic Progression of Rectal Cancer. Translational Oncology, 2019, 12, 1038-1044.	3.7	39
24	Comparison of Intravoxel incoherent motion imaging and multiecho dynamic contrastâ€based MRI in rectal cancer. Journal of Magnetic Resonance Imaging, 2019, 50, 1114-1124.	3.4	10
25	An experimental strategy unveiling exosomal microRNAs 486â€5p, 181aâ€5p and 30dâ€5p from hypoxic tumour cells as circulating indicators of highâ€risk rectal cancer. Journal of Extracellular Vesicles, 2019, 8, 1567219.	12.2	68
26	Markers of Mitochondrial Metabolism in Tumor Hypoxia, Systemic Inflammation, and Adverse Outcome of Rectal Cancer. Translational Oncology, 2019, 12, 76-83.	3.7	16
27	Learning radiation oncology in Europe: Results of the ESTRO multidisciplinary survey. Clinical and Translational Radiation Oncology, 2018, 9, 61-67.	1.7	26
28	Systemic immune response induced by oxaliplatin-based neoadjuvant therapy favours survival without metastatic progression in high-risk rectal cancer. British Journal of Cancer, 2018, 118, 1322-1328.	6.4	26
29	Large-scale reduction of tyrosine kinase activities in human monocytes stimulated in vitro with N. meningitidis. PLoS ONE, 2018, 13, e0181912.	2.5	2
30	Circulating vitamin D during neoadjuvant therapy in high-risk rectal cancer.. Journal of Clinical Oncology, 2018, 36, e15532-e15532.	1.6	0
31	Diffusion-weighted magnetic resonance imaging of rectal cancer: tumour volume and perfusion fraction predict chemoradiotherapy response and survival. Acta OncolÃ³gica, 2017, 56, 813-818.	1.8	33
32	Dynamic multi-echo DCE- and DSC-MRI in rectal cancer: Low primary tumor K^{trans} and Î”R2* peak are significantly associated with lymph node metastasis. Journal of Magnetic Resonance Imaging, 2017, 46, 194-206.	3.4	21
33	Use of non-invasive imaging to monitor response to aflibercept treatment in murine models of colorectal cancer liver metastases. Clinical and Experimental Metastasis, 2017, 34, 51-62.	3.3	16
34	Induction of Apoptosis in Intestinal Toxicity to a Histone Deacetylase Inhibitor in a Phase I Study with Pelvic Radiotherapy. Cancer Research and Treatment, 2017, 49, 374-386.	3.0	4
35	Pro-survival responses to the dual inhibition of anti-apoptotic Bcl-2 family proteins and mTOR-mediated signaling in hypoxic colorectal carcinoma cells. BMC Cancer, 2016, 16, 531.	2.6	6
36	Hypoxia regulates Notch-3 mRNA and receptor activation in prostate cancer cells. Heliyon, 2016, 2, e00104.	3.2	10

#	Article	IF	Citations
37	High tumor glycine concentration is an adverse prognostic factor in locally advanced rectal cancer. Radiotherapy and Oncology, 2016, 118, 393-398.	0.6	24
38	Individual tumor volume responses to short-course oxaliplatin-containing induction chemotherapy in locally advanced rectal cancer â€“ Targeting the tumor for radiation sensitivity?. Radiotherapy and Oncology, 2016, 119, 505-511.	0.6	7
39	Sulfamate inhibitor S4 influences carbonic anhydrase IX ectodomain shedding in colorectal carcinoma cells. Journal of Enzyme Inhibition and Medicinal Chemistry, 2016, 31, 779-786.	5.2	9
40	Systemic release of osteoprotegerin during oxaliplatin-containing induction chemotherapy and favorable systemic outcome of sequential radiotherapy in rectal cancer. Oncotarget, 2016, 7, 34907-34917.	1.8	14
41	Tumor phosphatidylinositol 3-kinase signaling in therapy resistance and metastatic dissemination of rectal cancer: Opportunities for signaling-adapted therapies. Critical Reviews in Oncology/Hematology, 2015, 95, 114-124.	4.4	15
42	Personalized radiotherapy: concepts, biomarkers and trial design. British Journal of Radiology, 2015, 88, 20150009.	2.2	31
43	MRI volumetry for prediction of tumour response to neoadjuvant chemotherapy followed by chemoradiotherapy in locally advanced rectal cancer. British Journal of Radiology, 2015, 88, 20150097.	2.2	24
44	Early increase in circulating carbonic anhydrase IX during neoadjuvant treatment predicts favourable outcome in locally advanced rectal cancer. BMC Cancer, 2015, 15, 543.	2.6	18
45	Biomarkers of Histone Deacetylase Inhibitor Activity in a Phase 1 Combined-Modality Study with Radiotherapy. PLoS ONE, 2014, 9, e89750.	2.5	7
46	Dynamic 18â€‰F-FDG PET for Assessment of Tumor Physiology in Two Breast Carcinoma Xenografts. Nuclear Medicine and Molecular Imaging, 2013, 47, 173-180.	1.0	7
47	Differential Inhibition of Ex-Vivo Tumor Kinase Activity by Vemurafenib in BRAF(V600E) and BRAF Wild-Type Metastatic Malignant Melanoma. PLoS ONE, 2013, 8, e72692.	2.5	28
48	Hypoxic Tumor Kinase Signaling Mediated by STAT5A in Development of Castration-Resistant Prostate Cancer. PLoS ONE, 2013, 8, e63723.	2.5	14
49	Longitudinal Magnetic Resonance Imaging-Based Assessment of Vascular Changes and Radiation Response in Androgen-Sensitive Prostate Carcinoma Xenografts under Androgen-Exposed and Androgen-Deprived Conditions. Neoplasia, 2010, 12, 818-825.	5.3	12
50	Preclinical dynamic¹⁸F-FDG PET â€“ tumor characterization and radiotherapy response assessment by kinetic compartment analysis. Acta OncolÃ³gica, 2010, 49, 914-921.	1.8	27
51	Inhibitory effects of oxaliplatin in experimental radiation treatment of colorectal carcinoma: does oxaliplatin improve 5-fluorouracil-dependent radiosensitivity?. Radiotherapy and Oncology, 2008, 86, 428-434.	0.6	31
52	Dynamic contrast enhanced magnetic resonance imaging of bladder cancer and implications for biological image-adapted radiotherapy. Acta OncolÃ³gica, 2008, 47, 1257-1264.	1.8	7
53	Noninvasive monitoring of radiation-induced treatment response using proton magnetic resonance spectroscopy and diffusion-weighted magnetic resonance imaging in a colorectal tumor model. Radiotherapy and Oncology, 2007, 85, 187-194.	0.6	27
54	Early Changes in Apparent Diffusion Coefficient Predict the Quantitative Antitumoral Activity of Capecitabine, Oxaliplatin, and Irradiation in HT29 Xenografts in Athymic Nude Mice. Neoplasia, 2007, 9, 392-400.	5.3	25